December 3, 2025

COLLEGE PARK, MD – December 1, 2025 - IonQ (NYSE: IONQ), the world’s leading quantum company, today announced an investment partnership with the Centre for Commercialization of Regenerative Medicine (CCRM) to accelerate next-generation therapeutic development using hybrid quantum and quantum-AI technologies. The partnership includes an investment commitment into CCRM’s new quantum-biotech initiatives and establishes IonQ as the core technology partner across CCRM’s global network of advanced therapy hubs.

COLUMBIA, Md., (November 24, 2025) — TEDCO, Maryland’s economic engine for technology companies, announced a recent $250,000 Pre-Seed Builder Fund investment in NasaClip, a woman- and minority-led startup which created a new device to assist in a painless, hands-free method for stopping nosebleeds. The Pre-Seed Builder Fund is housed under the umbrella of TEDCO’s Social Impact Funds.

“Nosebleeds can be nerve-wracking and scary, but, more often than not, they are non-life-threatening,” said Elizabeth Clayborne, MD, CEO and founder of NasaClip. “Unfortunately, the care for nosebleeds offered at the emergency department tends...

This episode brings together three leaders working at the intersection of pediatric innovation, health security, and early-stage commercialization. Kolaleh Eskandanian, Program Director of SPARK, is joined by founders Dori Jones of AcQumen Medical and Jugal Suthar of Vesynta for a conversation about advancing breakthrough solutions for children. They discuss the mission behind the BARDA-funded SPARK for Innovations in Pediatrics Hub at Children's National Hospital, the challenges of developing technologies for pediatric populations, and the impact of public-private partnerships in moving lifesaving tools to market. Dori and Jugal share what their companies are building, the inflection points that shaped their journeys, and how BioHealth Innovation’s Entrepreneur-in-Residence program supported their progress. The group reflects on lessons learned, the value of mentorship, and how collaborative accelerator ecosystems help drive breakthroughs in pediatric care, preparedness, and health equity.

The Department of Health and Human Services on Monday officially announced Alicia Jackson as the new director of the Advanced Research Projects Agency for Health, even as ARPA-H is beset by budget cuts.

Jackson, who most recently founded the women’s health startup Evernow, formerly served as deputy director of the Defense Advanced Research Projects Agency’s Biological Technologies Office. Her work there involved directing the agency’s investments across various biodefense projects as well as its biomanufacturing and drug development contracts, according to the HHS’ news release.

Jackson will bring that experience over to ARPA-H, which describes itself on its website as a funding agency dedicated to supporting research on “transformative biomedical and health breakthroughs – ranging from the molecular to the societal.”

Recently, for instance, the agency earmarked up to $100 million for quantitative measures of mental and behavioral...

The Greater Baltimore Committee’s Regional Innovation Office (RIO) has submitted a strengthened Phase 3 EDA Tech Hub proposal—one that places new venture creation, dual-use biomanufacturing, and federal alignment at the center of a strategy to position the Baltimore Region as a national leader in a rapidly emerging technology space.

From the outset, the proposal responds directly to federal priorities around national security, commercialization, and dual-use technology development. It emphasizes the critical role of early-stage and scaling ventures—particularly those at...

If your organization follows a calendar-year budget and has funds that need to be committed before the end of 2025, you can lock in your sponsorship for the 2026 BioHealth Capital Region Week now. Early confirmations help us plan next year’s program and allow you to reserve your place in advance.

We are already reviewing improvements for 2026, including moving table sponsors to a higher-traffic area and shifting the registration desk closer to the front entrance. Suggestions for speakers, panels, and themes are welcome.

To confirm your support or share ideas, email Rich Bendis at rbendis@biohealthinnovation.org and Andy Eckert at aeckert@biohealthinnovation.org

. We appreciate your partnership and look forward to building another strong BHCR Week together.

RESTON, Va., Nov. 25, 2025 /PRNewswire/ -- VSI® Spine Surgeon Dr. Christopher Good has achieved a historic milestone in robotic spine surgery, performing the world's first minimally invasive robotic Bertolotti's resection surgery at Reston Hospital Center (HCA Virginia Health System). This first-ever procedure introduces a transformative surgical option for patients suffering from chronic low back pain caused by Bertolotti syndrome, an underdiagnosed spinal condition affecting an estimated 4-8% of the population.

Traditionally, resection surgery for Bertolotti syndrome can require large incisions and significant tissue disruption to access the deeply positioned transitional bone. Dr. Good's innovative approach replaces this extensive exposure with a precisely planned, robot-guided procedure that dramatically reduces surgical impact.

GAITHERSBURG, Md., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and metabolic diseases, today announced a CEO succession plan under which Vipin Garg, Ph.D. will step down as the Company’s President and Chief Executive Officer effective January 1, 2026. Altimmune’s Chairman of the Board, Jerry Durso, will assume the role of President and Chief Executive Officer and retain his position as Chairman. To facilitate a smooth transition, Dr. Garg will serve as an advisor to the Company through June 30, 2026.

Since 2018, Dr. Garg has guided Altimmune into becoming an agile, clinical-stage company. During his tenure, the Company’s lead pipeline candidate...

The new edition reviews venture, convertible note, and SAFE activity from the third quarter and tracks how deal terms are shifting across stages. It highlights rising valuations and larger round sizes for many companies, reinforcing that high-quality teams and technologies are still attracting premium pricing and sizable checks. The report also underscores how SAFEs have become the default instrument at the pre-Seed stage, with more than 90 percent of sub-million-dollar fundraises using this structure. Readers will find practical insights from David Grawemeyer on common fundraising mistakes, building a compliance-focused team, and navigating today’s regulatory expectations. The report also introduces Breakthrough Minds, a new podcast that features candid conversations with founders, operators, and thought leaders behind breakthrough innovations and offers another window into how early-stage companies are thinking about growth.